SE0202465D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE0202465D0
SE0202465D0 SE0202465A SE0202465A SE0202465D0 SE 0202465 D0 SE0202465 D0 SE 0202465D0 SE 0202465 A SE0202465 A SE 0202465A SE 0202465 A SE0202465 A SE 0202465A SE 0202465 D0 SE0202465 D0 SE 0202465D0
Authority
SE
Sweden
Prior art keywords
new compounds
formula
receptor agonists
acetylcholine receptor
nicotinic acetylcholine
Prior art date
Application number
SE0202465A
Other languages
English (en)
Swedish (sv)
Inventor
Eifion Phillips
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0202465A priority Critical patent/SE0202465D0/xx
Publication of SE0202465D0 publication Critical patent/SE0202465D0/xx
Priority to MXPA05001584A priority patent/MXPA05001584A/es
Priority to BR0313233-1A priority patent/BR0313233A/pt
Priority to CNB038192578A priority patent/CN100436453C/zh
Priority to KR1020057002266A priority patent/KR20060005334A/ko
Priority to PCT/SE2003/001276 priority patent/WO2004016616A1/en
Priority to JP2004529001A priority patent/JP2005539030A/ja
Priority to EP03788213A priority patent/EP1539764B1/en
Priority to US10/524,482 priority patent/US20060052368A1/en
Priority to AU2003248590A priority patent/AU2003248590B2/en
Priority to AT03788213T priority patent/ATE430152T1/de
Priority to DE60327441T priority patent/DE60327441D1/de
Priority to CA002493246A priority patent/CA2493246A1/en
Priority to IL16642505A priority patent/IL166425A0/xx
Priority to ZA200501227A priority patent/ZA200501227B/en
Priority to NO20051260A priority patent/NO20051260L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SE0202465A 2002-08-14 2002-08-14 New compounds SE0202465D0 (sv)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SE0202465A SE0202465D0 (sv) 2002-08-14 2002-08-14 New compounds
CA002493246A CA2493246A1 (en) 2002-08-14 2003-08-13 Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists
JP2004529001A JP2005539030A (ja) 2002-08-14 2003-08-13 ニコチン性アセチルコリン作用剤としてのアリール置換ジアザビシクロアルカン
US10/524,482 US20060052368A1 (en) 2002-08-14 2003-08-13 Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists
CNB038192578A CN100436453C (zh) 2002-08-14 2003-08-13 作为烟碱性乙酰胆碱激动剂的芳基取代的二氮杂双环烷烃
KR1020057002266A KR20060005334A (ko) 2002-08-14 2003-08-13 니코틴성 아세틸콜린 아고니스트로서의 아릴 치환된디아자비시클로알칸
PCT/SE2003/001276 WO2004016616A1 (en) 2002-08-14 2003-08-13 Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists.
MXPA05001584A MXPA05001584A (es) 2002-08-14 2003-08-13 Diazabiciloalcanos sustituidos con arilo como agonistas de acetilcolina nicotinicos.
EP03788213A EP1539764B1 (en) 2002-08-14 2003-08-13 Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists.
BR0313233-1A BR0313233A (pt) 2002-08-14 2003-08-13 Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, e, composição farmacêutica
AU2003248590A AU2003248590B2 (en) 2002-08-14 2003-08-13 Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists
AT03788213T ATE430152T1 (de) 2002-08-14 2003-08-13 Aryl-substituierte diazabicycloalkane als nikotinische acetylcholinagonisten
DE60327441T DE60327441D1 (de) 2002-08-14 2003-08-13 Aryl-substituierte diazabicycloalkane als nikotinische acetylcholinagonisten
IL16642505A IL166425A0 (en) 2002-08-14 2005-01-20 Aryl-substituted diazabicyclkanes as nicotinic acetylcholine agonists
ZA200501227A ZA200501227B (en) 2002-08-14 2005-02-10 Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists
NO20051260A NO20051260L (no) 2002-08-14 2005-03-11 Arylsubstituerte diazabicykloalkaner som nikotinacetylcholinagonister

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202465A SE0202465D0 (sv) 2002-08-14 2002-08-14 New compounds

Publications (1)

Publication Number Publication Date
SE0202465D0 true SE0202465D0 (sv) 2002-08-14

Family

ID=20288753

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0202465A SE0202465D0 (sv) 2002-08-14 2002-08-14 New compounds

Country Status (16)

Country Link
US (1) US20060052368A1 (es)
EP (1) EP1539764B1 (es)
JP (1) JP2005539030A (es)
KR (1) KR20060005334A (es)
CN (1) CN100436453C (es)
AT (1) ATE430152T1 (es)
AU (1) AU2003248590B2 (es)
BR (1) BR0313233A (es)
CA (1) CA2493246A1 (es)
DE (1) DE60327441D1 (es)
IL (1) IL166425A0 (es)
MX (1) MXPA05001584A (es)
NO (1) NO20051260L (es)
SE (1) SE0202465D0 (es)
WO (1) WO2004016616A1 (es)
ZA (1) ZA200501227B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
SE0202430D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
PL210065B1 (pl) 2002-09-25 2011-11-30 Memory Pharm Corp Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków
US7456171B2 (en) * 2002-10-08 2008-11-25 Sanofi-Aventis 1,4-Diazabicyclo[3.2.2]nonanecarboxamide derivatives, preparation and therapeutic use thereof
ES2708552T3 (es) 2002-12-20 2019-04-10 Niconovum Ab Método para la preparación de un material particulado que contiene nicotina con una celulosa cristalina (en particular MCC)
BRPI0407216A (pt) * 2003-02-27 2006-01-24 Neurosearch As Derivado de arila diazabicìclica, composição farmacêutica, uso de um derivado de arila diazabicìclica, e, método de tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou uma condição
JP4824578B2 (ja) 2003-12-22 2011-11-30 メモリー・ファーマシューティカルズ・コーポレイション インドール類、１，２−ベンズイソオキサゾール類、および１，２−ベンゾイソチアゾール類、ならびにそれらの製造と使用
TW200529860A (en) * 2003-12-22 2005-09-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
CN100445285C (zh) * 2003-12-22 2008-12-24 阿斯利康(瑞典)有限公司 烟碱性乙酰胆碱受体配体
FR2865208B1 (fr) * 2004-01-16 2009-01-16 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique
EP1713810B1 (en) * 2004-02-04 2010-12-29 NeuroSearch A/S Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
JP2007528420A (ja) * 2004-03-11 2007-10-11 グラクソ　グループ　リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
KR101176670B1 (ko) 2004-03-25 2012-08-23 메모리 파마슈티칼스 코포레이션 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸, 및그의 제조법 및 용도
EP1742944B1 (en) 2004-04-22 2010-11-10 Memory Pharmaceuticals Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
WO2005111038A2 (en) * 2004-05-07 2005-11-24 Memory Pharmaceuticals Corporation 1h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
MX2007003331A (es) 2004-11-30 2007-06-05 Neurosearch As Nuevos derivados de arilo diazabiciclico.
AU2005319248A1 (en) 2004-12-22 2006-06-29 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
BRPI0619672A2 (pt) * 2005-11-09 2011-10-11 Memory Pharm Corp composto, composição farmacêutica, e, uso de um composto
EP1987032A1 (en) 2006-02-14 2008-11-05 NeuroSearch A/S 3, 9-diazabicyclo(3.3.1)non-3-yl-aryl methanone derivatives as nicotinic acetylcholine receptor agonists
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
TWI454262B (zh) * 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
RU2010140613A (ru) * 2008-03-05 2012-04-10 Таргасепт, Инк. (Us) Амиды диазабициклоалканов, селективные в отношении подтипа никотиновых ацетилхолиновых рецепторов
CN102131791B (zh) 2008-06-20 2014-12-24 阿斯利康(瑞典)有限公司 二苯并硫杂氮杂*衍生物及其用途
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
EP2571874B1 (en) 2010-05-17 2016-03-30 Forum Pharmaceuticals Inc. A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
EP2657237B1 (en) * 2010-12-22 2015-05-20 Tosoh Corporation Cyclic amine compound, and process for producing polyurethane resin using same
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
US10214476B2 (en) 2011-12-30 2019-02-26 Ecole Nationale Superieure De Chimie De Clermont Ferrand Pain relief compounds
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
US8609162B2 (en) 2012-10-04 2013-12-17 Invivo Beverages Llc Integrated neuromodulation system for mood enhancement of a living human subject
ES2694299T3 (es) 2013-02-07 2018-12-19 Heptares Therapeutics Limited Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4
AU2014282977B2 (en) 2013-06-21 2018-06-14 Takeda Pharmaceutical Company Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
WO2019005874A1 (en) 2017-06-26 2019-01-03 The Trustees Of Columbia University In The City Of New York CHOLINERGIC AGONISM FOR THE TREATMENT OF PANCREATIC CANCER
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3281423A (en) * 1964-02-03 1966-10-25 Merck & Co Inc 1, 3-ethanopiperazines and process
US4895943A (en) * 1988-10-25 1990-01-23 Pfizer Inc. Preparation of 1,4-diazabicyclo(3.2.2)nonane
US5679673A (en) * 1992-09-24 1997-10-21 The United States Of America, Represented By The Department Of Health And Human Services Aralkyl bridged diazabicycloalkane derivatives for CNS disorders
FR2791678B1 (fr) * 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
FR2809730B1 (fr) * 2000-05-31 2002-07-19 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.2] nonanebenzoxazole, -benzothiazole et -benzimidazole, leur preparation et leur application therapeutique
FR2809731B1 (fr) * 2000-05-31 2002-07-19 Sanofi Synthelabo Derives de 1,4-diazabicyclo-[3.2.2] nonane-pheylisoxazole, leur preparation et leur application en therapeutique
FR2809732B1 (fr) * 2000-05-31 2002-07-19 Sanofi Synthelabo DERIVES DE 4(-2-PHENYLTHIAZOL-5-yl)-1,4-DIAZABICYCLO-[3.2.2] NONANE, LEUR PREPARATION ET LEUR APPLICATION ENTHERAPEUTIQUE
US20020086871A1 (en) * 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
SE0202430D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
BRPI0407216A (pt) * 2003-02-27 2006-01-24 Neurosearch As Derivado de arila diazabicìclica, composição farmacêutica, uso de um derivado de arila diazabicìclica, e, método de tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou uma condição
CN100445285C (zh) * 2003-12-22 2008-12-24 阿斯利康(瑞典)有限公司 烟碱性乙酰胆碱受体配体
TW200529860A (en) * 2003-12-22 2005-09-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands

Also Published As

Publication number Publication date
IL166425A0 (en) 2006-01-15
NO20051260L (no) 2005-05-10
ATE430152T1 (de) 2009-05-15
CN1675215A (zh) 2005-09-28
AU2003248590A1 (en) 2004-03-03
CN100436453C (zh) 2008-11-26
US20060052368A1 (en) 2006-03-09
AU2003248590B2 (en) 2008-03-20
EP1539764A1 (en) 2005-06-15
BR0313233A (pt) 2005-06-14
JP2005539030A (ja) 2005-12-22
WO2004016616A1 (en) 2004-02-26
MXPA05001584A (es) 2005-04-25
DE60327441D1 (de) 2009-06-10
EP1539764B1 (en) 2009-04-29
ZA200501227B (en) 2006-07-26
CA2493246A1 (en) 2004-02-26
KR20060005334A (ko) 2006-01-17

Similar Documents

Publication Publication Date Title
SE0202465D0 (sv) New compounds
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
ATE346070T1 (de) Purinderivate als kinaseinhibitoren
DK1761520T3 (da) Kinaseinhibitorer
SE0000540D0 (sv) New compounds
DE60335359D1 (de) Phthalazinonderivate
ATE360627T1 (de) Pyrrolidindion-substituierte piperidin- phthalazone als pde4-inhibitoren
NO20076306L (no) Bicykliske derivater som modulatorer av ionekanaler
UY29612A1 (es) Compuestos quimicos ii
CY1113648T1 (el) Παραγωγα πυριδινονης για θεραπεια αθηροσκληρωσης
EA200601391A1 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
CR20120421A (es) Compuestos de aminohetetoarilo o sustituidos con pirazol como inhibidores de proteina quinasa
ATE490253T1 (de) Synthese von 5-substituierten 7-azaindolen und 7- azaindolinen
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
NO20031001L (no) Polyarylkarboksamider nyttige som lipidsenkende midler
ATE429427T1 (de) Pyrimidinderivate als orexin-rezeptorantagonisten
CY1109680T1 (el) Υποκατεστημενες πυριδινονες ως ρυθμιστες της ρ38 μαρ κινασης
ATE422198T1 (de) Arylsulfonylnaphthalinderivate als 5ht2a- antagonisten
ATE302775T1 (de) Carbolinderivate
NO20071108L (no) Nye 4-benzylidenpiperidinderivater
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
ATE384039T1 (de) Indanderivate als muscarinrezeptoragonisten
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
CY1107156T1 (el) Νεα μεθοδος συνθεσης του (7-μεθοξυ-3,4-διυδρο-1-ναφθαλινυλ) ακετονιτριλιου και εφαρμογη στη συνθεση της αγομελατινης
ATE346067T1 (de) Carbolinderivate